The company is seeking NY State approval for its lab, which would allow it to offer both tests as LDTs, hopefully by the end of this year or early next.
The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer.
The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
The blood-based test, called Melaseq, measures 38 circulating microRNAs that regulate processes that melanoma cells undergo as they become malignant.
The company said the NIH funding will enable it to further validate the saliva-based test and prepare it for commercial launch later this year.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
The firm has collected evidence supporting the use of its PancraGen to providing the same molecular information for samples from biliary strictures and solid pancreatic lesions as it has done for years in pancreatic cyst fluid.
Cigna began covering the company's ThyGeNext next-generation sequencing-based test for thyroid cancer risk assessment in 2017.
The company beat the analysts' average estimate on the top line but missed it on the bottom line as it posted a net loss of $3.2 million.
The five-year-old firm recently completed a clinical trial of the real-time PCR-based test, called ProALL-BM, on patients from a European National Registry Study.